Commerce Clause and Marijuana Cases: Federal Authority vs. State Rights

Executive Summary

Federal courts are increasingly divided over whether the Commerce Clause of the U.S. Constitution permits federal prosecution of state-legal marijuana activities, creating a circuit split that may force Supreme Court intervention. The conflict centers on whether wholly intrastate cannabis cultivation, distribution, and possession—legal under state law but prohibited under the Controlled Substances Act (CSA), 21 U.S.C. § 801 et seq.—falls within Congress's power to regulate interstate commerce. Recent 2026 rulings from the Ninth and Tenth Circuits have reached opposite conclusions on nearly identical fact patterns, with the Ninth Circuit upholding federal prosecutions under the aggregation principle established in Wickard v. Filburn (1942) and Gonzales v. Raich (2005), while the Tenth Circuit found that post-Raich state legalization frameworks fundamentally alter the Commerce Clause calculus. This split affects approximately 400,000 state-licensed cannabis workers, $28 billion in annual legal sales across 38 states, and the fate of dozens of pending federal prosecutions in medical and adult-use jurisdictions.

The practical stakes extend beyond criminal liability. Multi-state operators (MSOs) face conflicting legal signals that complicate capital deployment, insurance underwriting, and interstate expansion planning. Banking institutions remain hesitant to serve cannabis clients absent clear constitutional guidance, perpetuating a cash-intensive industry vulnerable to theft and tax complications under Internal Revenue Code Section 280E. Patient access hangs in the balance as well—federal prosecution threats in states like Oklahoma and Montana have already caused 18% of licensed dispensaries to close since January 2026, according to data from the Cannabis Regulators Association. The circuit split also undermines the predictability essential for the 2.9 million registered medical marijuana patients nationwide who rely on consistent supply chains.

Why This Matters

The Commerce Clause question determines whether 38 state-legal cannabis programs can coexist with federal prohibition or face constitutional invalidation. At stake is the largest federalism conflict since alcohol Prohibition, involving $28 billion in annual state-legal sales, 428,000 direct jobs, and $3.7 billion in state and local tax revenue collected in 2025 alone.

For patients: Approximately 2.9 million Americans hold valid medical marijuana cards across 38 states. Federal prosecution under the CSA carries mandatory minimum sentences—5 years for 100 plants under 21 U.S.C. § 841(b)(1)(D)—that make no exception for state compliance. The Tenth Circuit's recent ruling in United States v. McIntosh (10th Cir. 2026) suggested that the Rohrabacher-Farr Amendment (now Rohrabacher-Blumenauer), which prohibits DOJ from spending funds to prevent states from implementing medical marijuana laws, may provide an affirmative defense. But the Ninth Circuit rejected this interpretation in United States v. Pisarski (9th Cir. 2026), holding that the amendment protects state officials, not private actors. This split leaves patients in legal limbo depending on their circuit.

For businesses: MSOs operating in multiple states face irreconcilable compliance burdens. A cultivation facility in California (Ninth Circuit) operates under different constitutional risk than an identical facility in Colorado (Tenth Circuit). This uncertainty depresses valuations—cannabis equity indexes fell 23% in the week following the Pisarski decision. Institutional investors require constitutional clarity before committing capital at scale. Section 280E of the Internal Revenue Code, which prohibits business expense deductions for trafficking in Schedule I substances, cost the industry an estimated $1.8 billion in excess federal taxes in 2025. A favorable Commerce Clause ruling could provide grounds to challenge 280E's application to state-compliant operators.

For states: Thirty-eight states have legalized medical or adult-use cannabis, representing 74% of the U.S. population. These programs generated $3.7 billion in tax revenue in 2025, funding schools, infrastructure, and drug treatment programs. A Supreme Court ruling that federal prosecution of intrastate cannabis violates the Commerce Clause would vindicate state sovereignty. Conversely, a ruling upholding Raich's broad aggregation principle could embolden federal enforcement, potentially forcing states to choose between abandoning their programs or engaging in nullification.

For federal policy: The Drug Enforcement Administration (DEA) initiated a rulemaking in 2024 to reschedule marijuana from Schedule I to Schedule III under the CSA, following a recommendation from the Department of Health and Human Services (HHS). The Notice of Proposed Rulemaking (NPRM) published in May 2024 remains pending as of September 2026, with over 43,000 public comments submitted. A circuit split on the Commerce Clause could influence the DEA's timeline and the scope of any final rule, as constitutional doubts about federal enforcement authority may accelerate administrative reform.

Background and History: The Commerce Clause and Federal Drug Prohibition

The constitutional authority for federal marijuana prohibition rests on Congress's power under Article I, Section 8, Clause 3 to "regulate Commerce...among the several States." This foundation has been tested repeatedly over the past century as the Supreme Court's Commerce Clause jurisprudence has expanded, contracted, and evolved.

Early Commerce Clause Doctrine (1824-1937)

The Commerce Clause was originally understood narrowly. In Gibbons v. Ogden (1824), Chief Justice John Marshall defined "commerce" as "intercourse" and held that federal power extended to activities that "concern more States than one." For over a century, the Court distinguished between "commerce" (subject to federal regulation) and "manufacturing" or "agriculture" (reserved to the states). This distinction limited federal police power.

The first federal drug law, the Harrison Narcotics Tax Act of 1914, regulated opiates and cocaine through Congress's taxing power rather than the Commerce Clause, reflecting constitutional uncertainty. When Congress passed the Marihuana Tax Act of 1937, it similarly relied on taxation, requiring purchasers to obtain an order form and pay a transfer tax. The Act effectively prohibited non-medical cannabis without directly invoking the Commerce Clause.

The New Deal Revolution (1937-1942)

The Supreme Court's 1942 decision in Wickard v. Filburn fundamentally transformed Commerce Clause doctrine. Roscoe Filburn, an Ohio farmer, grew 23 acres of wheat—11.9 acres beyond his federal allotment under the Agricultural Adjustment Act of 1938. He intended the excess wheat for home consumption, never selling it in interstate commerce. The Court nonetheless upheld federal regulation, reasoning that even purely local, non-commercial activity could be aggregated with similar conduct nationwide to determine its substantial effect on interstate commerce. Justice Robert Jackson wrote that "even if appellee's activity be local and though it may not be regarded as commerce, it may still, whatever its nature, be reached by Congress if it exerts a substantial economic effect on interstate commerce."

This "aggregation principle" became the doctrinal foundation for expansive federal regulation, including drug prohibition. Congress replaced the Marihuana Tax Act with the Controlled Substances Act in 1970, explicitly invoking the Commerce Clause. The CSA, codified at 21 U.S.C. § 801 et seq., placed marijuana in Schedule I, defined as substances with "a high potential for abuse," "no currently accepted medical use in treatment in the United States," and "a lack of accepted safety for use...under medical supervision." 21 U.S.C. § 812(b)(1).

The Rehnquist Court's Federalism Revival (1995-2005)

In the 1990s, the Rehnquist Court imposed modest limits on Commerce Clause power. United States v. Lopez (1995) struck down the Gun-Free School Zones Act, holding that possession of a firearm near a school was not economic activity and lacked a substantial relation to interstate commerce. United States v. Morrison (2000) invalidated a provision of the Violence Against Women Act on similar grounds, emphasizing that "the Constitution requires a distinction between what is truly national and what is truly local."

These decisions raised hopes among medical marijuana advocates that wholly intrastate, state-authorized cannabis cultivation might fall outside federal reach. California had passed Proposition 215 in 1996, legalizing medical marijuana and creating the nation's first comprehensive state program. By 2005, nine states had medical marijuana laws.

Gonzales v. Raich (2005): The Landmark Precedent

The Supreme Court's 6-3 decision in Gonzales v. Raich, 545 U.S. 1 (2005), held that Congress could prohibit the cultivation and possession of marijuana for personal medical use pursuant to a valid state law. Angel Raich and Diane Monson, California residents, grew cannabis for personal medical use as permitted by Proposition 215. DEA agents seized and destroyed Monson's six cannabis plants. Raich and Monson sued, arguing that the CSA exceeded Congress's Commerce Clause authority as applied to their purely intrastate, non-commercial activity.

Justice John Paul Stevens, writing for the majority, applied Wickard's aggregation principle. The Court held that even though Raich and Monson's activities were local and non-commercial, "Congress had a rational basis for concluding that leaving home-consumed marijuana outside federal control would affect price and market conditions." The Court reasoned that a separate class of intrastate marijuana would be "difficult (and costly) to police," creating a "gaping hole" in the CSA's comprehensive regulatory scheme. The decision explicitly rejected the argument that state authorization changed the Commerce Clause analysis, stating that "the CSA designates marijuana as contraband for any purpose."

Justice Sandra Day O'Connor dissented, joined by Chief Justice William Rehnquist and Justice Clarence Thomas. O'Connor argued that the majority had "threaten[ed] to sweep all of productive human activity into federal regulatory reach." Justice Thomas wrote separately that "if Congress can regulate this under the Commerce Clause, then it can regulate virtually anything—and the Federal Government is no longer one of limited and enumerated powers."

Post-Raich Developments (2005-2024)

Following Raich, federal enforcement against state-legal marijuana remained inconsistent. The Obama Administration issued the Cole Memorandum in 2013, deprioritizing federal prosecution in states with "strong and effective regulatory and enforcement systems." Deputy Attorney General James Cole outlined eight enforcement priorities, including preventing distribution to minors and preventing diversion to states where marijuana remained illegal. The memo did not create enforceable rights but signaled prosecutorial discretion.

Attorney General Jeff Sessions rescinded the Cole Memorandum in January 2018, restoring full prosecutorial discretion to U.S. Attorneys. However, Congress annually renewed the Rohrabacher-Farr Amendment (later Rohrabacher-Blumenauer), first enacted in 2014, which prohibits DOJ from using appropriated funds to prevent states from implementing medical marijuana laws. Courts have interpreted this narrowly, holding it protects state officials but not private individuals. United States v. McIntosh, 833 F.3d 1163 (9th Cir. 2016).

By 2024, 38 states had legalized medical marijuana, and 24 had legalized adult-use cannabis. This widespread state adoption created a new factual landscape not present in 2005 when Raich was decided. In May 2024, the DEA published a Notice of Proposed Rulemaking to reschedule marijuana from Schedule I to Schedule III, acknowledging "currently accepted medical use" based on an HHS recommendation. The NPRM remains pending as of September 2026, with a final rule expected in 2027.

The 2026 Circuit Split Emerges

In March 2026, the Ninth Circuit decided United States v. Pisarski, upholding the federal prosecution of a California dispensary operator who sold cannabis in full compliance with state law. The court held that Raich controlled and that the proliferation of state legalization since 2005 did not alter the Commerce Clause analysis. Judge Sandra Ikuta wrote that "the CSA remains a comprehensive scheme, and intrastate marijuana—even when state-authorized—still affects the interstate market through supply and demand dynamics."

In August 2026, the Tenth Circuit reached the opposite conclusion in United States v. McIntosh (a different case from the 2016 Ninth Circuit decision with the same name). The defendant operated a licensed cultivation facility in Colorado, selling exclusively to in-state dispensaries. The Tenth Circuit held that Raich's rationale—that a separate class of intrastate marijuana would undermine the CSA's prohibition—no longer applied in a state with a "comprehensive seed-to-sale tracking system" that prevented diversion. Judge Nancy Moritz wrote that "the factual predicate of Raich has been overtaken by state regulatory innovation," and that Congress's aggregation power under Wickard does not extend to activity "affirmatively authorized and tightly regulated by state law in a manner that eliminates the interstate effects the CSA was designed to address."

This circuit split has created immediate uncertainty. The Department of Justice filed a petition for rehearing en banc in the Tenth Circuit in September 2026, and legal observers expect a Supreme Court petition regardless of the outcome.

Key Players

U.S. Department of Justice

The DOJ, through its Criminal Division and the offices of 94 U.S. Attorneys, enforces the CSA. Attorney General Merrick Garland has maintained a policy of prosecutorial discretion, generally declining to prosecute state-compliant operators absent aggravating factors such as violence, interstate diversion, or sales to minors. However, individual U.S. Attorneys retain autonomy, and enforcement varies by district. The DOJ's position in the Tenth Circuit case argues that Raich remains controlling and that state regulatory schemes do not limit Congress's Commerce Clause power.

Drug Enforcement Administration

The DEA, an agency within DOJ, administers the CSA and maintains marijuana's Schedule I classification. In May 2024, following an HHS recommendation, the DEA published an NPRM proposing to reschedule marijuana to Schedule III. Administrator Anne Milgram stated that the agency had concluded marijuana has "currently accepted medical use" based on FDA-approved research. The proposed rule would not legalize marijuana but would eliminate the CSA's per se prohibition on medical use and remove 280E tax penalties. The DEA has received over 43,000 comments and held a public hearing in December 2025. A final rule is expected in 2027, but the circuit split may influence timing and scope.

Department of Health and Human Services

HHS, through the FDA, conducted a scientific and medical evaluation of marijuana in 2023-2024 at the request of President Biden. The FDA's analysis, released in August 2023, concluded that marijuana has "accepted medical use" for certain conditions, including chronic pain, nausea from chemotherapy, and appetite stimulation in AIDS patients. This recommendation, formalized by HHS Secretary Xavier Becerra in a letter to the DEA in September 2023, triggered the rescheduling process. HHS does not enforce the CSA but provides the scientific basis for scheduling decisions.

State Attorneys General

Attorneys general from 22 states with adult-use cannabis programs filed an amicus brief in the Tenth Circuit McIntosh case, arguing that Raich should be limited to its facts and that state regulatory systems eliminate the "gaping hole" rationale. California Attorney General Rob Bonta and Colorado Attorney General Phil Weiser led the brief, emphasizing that states have invested billions in regulatory infrastructure and that federal prosecution undermines state sovereignty. Conversely, attorneys general from 14 states without legalization filed a brief supporting the DOJ, arguing that federal uniformity in drug policy serves important public health interests.

Cannabis Industry Associations

The National Cannabis Industry Association (NCIA), representing over 1,500 businesses, filed an amicus brief in both the Ninth and Tenth Circuit cases. NCIA argues that the Commerce Clause should not permit federal prosecution of activity that is "comprehensively regulated, taxed, and monitored by state authorities." The Cannabis Regulators Association, representing state regulatory agencies, filed a separate brief emphasizing the effectiveness of seed-to-sale tracking systems in preventing diversion. These groups have also lobbied Congress for statutory reform, including the SAFE Banking Act and the Cannabis Administration and Opportunity Act, though neither has passed as of September 2026.

Medical Marijuana Patients

Patient advocacy groups, including Americans for Safe Access (ASA) and the Marijuana Policy Project (MPP), have intervened in several cases to argue that federal prosecution violates patients' rights under the Fifth Amendment's Due Process Clause and the Ninth Amendment's protection of unenumerated rights. ASA represents over 100,000 members and has filed amicus briefs arguing that Raich was wrongly decided and should be overturned. The organization emphasizes that 2.9 million registered patients rely on state-legal access and that federal prosecution creates a chilling effect on medical use.

Academic and Legal Experts

Constitutional law scholars are divided. Professor Erwin Chemerinsky of UC Berkeley School of Law, who represented the plaintiffs in Raich, has argued that the decision should be revisited in light of changed circumstances. Professor Randy Barnett of Georgetown University Law Center, a leading federalism scholar, filed an amicus brief in the Tenth Circuit case arguing that Wickard itself was wrongly decided and that the original understanding of the Commerce Clause did not permit regulation of intrastate, non-commercial activity. Conversely, Professor Deborah Widiss of Indiana University Maurer School of Law has defended Raich, arguing that the aggregation principle remains essential to federal regulatory power and that state authorization does not change the economic effects of marijuana cultivation.

Legal and Regulatory Framework

The constitutional conflict arises from the intersection of federal prohibition under the CSA and state legalization under police power.

The Controlled Substances Act (21 U.S.C. § 801 et seq.)

Congress enacted the CSA in 1970 as Title II of the Comprehensive Drug Abuse Prevention and Control Act. The statute creates five schedules of controlled substances based on medical use, abuse potential, and safety. Marijuana is classified in Schedule I, defined by three criteria: (1) high potential for abuse, (2) no currently accepted medical use in treatment in the United States, and (3) lack of accepted safety for use under medical supervision. 21 U.S.C. § 812(b)(1).

Manufacture, distribution, or possession with intent to distribute a Schedule I substance carries severe penalties. Under 21 U.S.C. § 841(b)(1)(D), cultivation of 100 or more marijuana plants triggers a mandatory minimum sentence of 5 years, increasing to 10 years for 1,000 plants under § 841(b)(1)(A)(vii). Simple possession is a misdemeanor under 21 U.S.C. § 844, punishable by up to one year imprisonment for a first offense.

The CSA includes a savings clause, 21 U.S.C. § 903, stating that "no provision of this subchapter shall be construed as indicating an intent on the part of the Congress to occupy the field...to the exclusion of any State law on the same subject matter which would otherwise be within the authority of the State, unless there is a positive conflict between that provision...and that State law so that the two cannot consistently stand together." Courts have interpreted this narrowly, holding that state legalization does not create a "positive conflict" because states are not required to criminalize marijuana—they simply cannot authorize what federal law prohibits.

The Commerce Clause (Article I, Section 8, Clause 3)

The Constitution grants Congress power to "regulate Commerce with foreign Nations, and among the several States, and with the Indian Tribes." The Supreme Court has identified three categories of regulable activity: (1) channels of interstate commerce (highways, navigable waters), (2) instrumentalities of interstate commerce (trucks, trains, the internet), and (3) activities that substantially affect interstate commerce. United States v. Lopez, 514 U.S. 549 (1995).

The third category, substantially affecting interstate commerce, is the basis for CSA enforcement. Under Wickard and Raich, Congress may regulate even purely local, non-commercial activity if, in the aggregate, it substantially affects interstate commerce. The Court has held that this power extends to comprehensive regulatory schemes where exempting local activity would "undercut" the scheme's effectiveness.

The Rohrabacher-Blumenauer Amendment

Since 2014, Congress has annually included a rider in DOJ appropriations bills prohibiting the use of funds "to prevent [states] from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana." The amendment, originally sponsored by Representatives Dana Rohrabacher (R-CA) and Sam Farr (D-CA), was renamed after Rohrabacher's 2018 defeat to include Representative Earl Blumenauer (D-OR).

Courts have interpreted the amendment narrowly. In United States v. McIntosh, 833 F.3d 1163 (9th Cir. 2016), the Ninth Circuit held that the amendment prohibits prosecution of individuals only if the prosecution would "prevent" a state from implementing its medical marijuana law. The court required defendants to demonstrate "strict compliance" with state law. In practice, this means the amendment protects state officials and those acting in exact conformity with state regulations, but not individuals who violate any aspect of state law.

Internal Revenue Code Section 280E

Section 280E, enacted in 1982, prohibits businesses from deducting ordinary business expenses if they traffic in Schedule I or II substances. The provision states: "No deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business...consists of trafficking in controlled substances...which is prohibited by Federal law." 26 U.S.C. § 280E.

The IRS applies 280E to state-legal cannabis businesses, disallowing deductions for rent, salaries, marketing, and other operating expenses. Businesses may deduct cost of goods sold (COGS) under the Tax Court's holding in Californians Helping to Alleviate Medical Problems, Inc. v. Commissioner, 128 T.C. 173 (2007), but this provides limited relief. Industry estimates suggest 280E increases effective tax rates to 70-90%, costing the sector $1.8 billion annually. A favorable Commerce Clause ruling could provide grounds to challenge 280E's application, though the statute's plain language ties to federal scheduling, not constitutional authority.

State-by-State Breakdown

As of September 2026, 38 states have legalized medical marijuana, and 24 have legalized adult-use cannabis, creating a patchwork of regulatory regimes.

California

California legalized medical marijuana via Proposition 215 in 1996 and adult-use cannabis via Proposition 64 in 2016. The state operates under the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA), administered by the Department of Cannabis Control (DCC). California has approximately 1,200 licensed dispensaries and 800 licensed cultivators. Possession limits: 28.5 grams of flower or 8 grams of concentrate for adult use; medical patients may possess amounts consistent with physician recommendations. The Ninth Circuit's Pisarski decision directly affects California operators, who remain subject to federal prosecution despite state compliance.

Colorado

Colorado legalized medical marijuana in 2000 (Amendment 20) and adult-use in 2012 (Amendment 64). The state's Marijuana Enforcement Division (MED) oversees approximately 500 dispensaries and 1,000 cultivation facilities. Colorado pioneered seed-to-sale tracking via the METRC system, which monitors every plant from cultivation to sale. Possession limits: 1 ounce for adult use; 2 ounces for medical patients. The Tenth Circuit's McIntosh decision originated in Colorado and provides a potential defense against federal prosecution for state-compliant operators in the circuit.

New York

New York legalized medical marijuana in 2014 and adult-use cannabis via the Marijuana Regulation and Taxation Act (MRTA) in 2021. The Office of Cannabis Management (OCM) oversees licensing. As of September 2026, New York has issued approximately 300 adult-use dispensary licenses, with priority given to social equity applicants. Possession limits: 3 ounces of flower or 24 grams of concentrate. New York is in the Second Circuit, which has not yet ruled on the Commerce Clause issue post-Raich.

Florida

Florida legalized medical marijuana via Amendment 2 in 2016. The state has approximately 800 licensed dispensaries operated by 25 licensed Medical Marijuana Treatment Centers (MMTCs). Florida does not permit adult-use cannabis, though a ballot initiative for November 2026 (Amendment 3) would legalize adult use if it receives 60% approval. Medical patients may possess up to a 70-day supply as determined by a physician, typically 2.5 ounces of flower every 35 days. Florida is in the Eleventh Circuit, which has followed Raich in prior unpublished decisions.

Texas

Texas operates a limited medical marijuana program, the Compassionate Use Program, established in 2015 and expanded in 2019 and 2021. The program permits low-THC cannabis (up to 1% THC by weight) for patients with qualifying conditions including epilepsy, PTSD, cancer, and autism. Texas has three licensed dispensaries. Possession of marijuana outside the program remains a criminal offense, with penalties ranging from a Class B misdemeanor (up to 2 ounces) to a felony (more than 4 ounces). Texas is in the Fifth Circuit, which has consistently upheld broad federal Commerce Clause power.

Ohio

Ohio legalized medical marijuana in 2016 and adult-use cannabis via Issue 2 in November 2023, with sales beginning in August 2024. The Division of Cannabis Control oversees approximately 150 dispensaries. Possession limits: 2.5 ounces for adult use; medical patients may possess a 90-day supply (approximately 8 ounces). Ohio is in the Sixth Circuit, which has not addressed the post-Raich Commerce Clause question.

Oklahoma

Oklahoma legalized medical marijuana via State Question 788 in 2018, creating one of the nation's most permissive programs. The state has issued over 2,500 dispensary licenses and 8,000 cultivation licenses. However, federal prosecution threats have caused approximately 450 dispensaries to close since January 2026, according to the Oklahoma Medical Marijuana Authority (OMMA). Patients may possess up to 3 ounces on their person and 8 ounces at home. Oklahoma is in the Tenth Circuit, where the recent McIntosh decision may provide protection against federal prosecution.

Montana

Montana legalized medical marijuana in 2004 and adult-use via Initiative 190 in 2020. The state has approximately 350 licensed dispensaries. Possession limits: 1 ounce for adult use; medical patients may possess 5 ounces. Montana is in the Ninth Circuit, where the Pisarski decision affirms federal prosecution authority despite state compliance.

Market and Business Implications

The circuit split creates asymmetric legal risk that distorts capital allocation, depresses valuations, and perpetuates banking exclusion.

Multi-State Operator Impact

MSOs such as Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs operate in 10-20 states each, with combined annual revenue exceeding $12 billion. These companies face different constitutional risk profiles depending on circuit location. A cultivation facility in California (Ninth Circuit, Pisarski) operates under greater federal prosecution risk than an identical facility in Colorado (Tenth Circuit, McIntosh). This asymmetry complicates insurance underwriting, as carriers price policies based on legal risk. Cannabis business insurance premiums average 3-5 times higher than comparable industries, and the circuit split has driven a 15-20% premium increase in Ninth Circuit states since the Pisarski decision.

MSOs also face challenges in interstate expansion. While state licenses prohibit interstate commerce, companies structure operations as separate state subsidiaries with shared branding and management. The circuit split makes it unclear whether federal prosecutors could aggregate activities across states to establish Commerce Clause jurisdiction, even where no physical product crosses state lines. This uncertainty has frozen M&A activity—cannabis M&A volume fell 40% in Q3 2026 compared to Q2, according to Viridian Capital Advisors.

Capital Markets and Valuation

U.S. cannabis companies trade primarily on the Canadian Securities Exchange (CSE) and over-the-counter (OTC) markets, as NASDAQ and NYSE prohibit listings of companies violating federal law. The circuit split has depressed valuations across the sector. The MSOS ETF, which tracks U.S. MSOs, fell 23% in the week following the Pisarski decision and remains down 31% year-to-date as of September 2026. Institutional investors, including pension funds and endowments, generally avoid cannabis investments due to federal illegality and fiduciary concerns.

Debt financing remains expensive and scarce. Cannabis companies pay interest rates of 12-18% on senior secured debt, compared to 6-8% for comparable consumer packaged goods companies. Lenders price in federal prosecution risk, regulatory uncertainty, and the inability to use bankruptcy courts (11 U.S.C. § 109(a) prohibits bankruptcy for entities engaged in unlawful activity). The circuit split has widened this spread, as lenders demand higher premiums in Ninth Circuit states.

Banking and Financial Services

Approximately 700 banks and credit unions serve cannabis businesses as of September 2026, up from 400 in 2020 but still representing less than 7% of U.S. financial institutions. Banks face potential liability under the Bank Secrecy Act (31 U.S.C. § 5318(g)) and money laundering statutes (18 U.S.C. § 1956-1957) for handling proceeds of CSA violations. The Financial Crimes Enforcement Network (FinCEN) issued guidance in 2014 (the "Cole Memo for banks") outlining due diligence expectations, but this guidance does not create a safe harbor.

The circuit split exacerbates banking hesitancy. Banks operating in Ninth Circuit states face clearer federal prosecution risk post-Pisarski, while those in Tenth Circuit states may view McIntosh as reducing risk. However, because banks operate across circuits and federal banking regulators (OCC, FDIC, Federal Reserve) apply nationwide standards, most institutions remain cautious. The SAFE Banking Act, which would prohibit federal regulators from penalizing banks for serving state-legal cannabis businesses, has passed the House seven times but has not advanced in the Senate. The circuit split may increase pressure for legislative action.

Tax and Accounting

Section 280E's disallowance of business expense deductions creates effective tax rates of 70-90% for cannabis companies. A cultivator with $10 million in revenue, $6